-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – LY-3885125 in Dyslipidemia
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - LY-3885125 in Dyslipidemia report and make more profitable business decisions. This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. LY-3885125 in Dyslipidemia Drug Details: LY-3885125 is under development for the treatment...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – AROPNPLA-3 in Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD)
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - AROPNPLA-3 in Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD) report and make more profitable business decisions. This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. AROPNPLA-3 in Metabolic Dysfunction-Associated Steatotic Liver Disease...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Pemafibrate in Hypercholesterolemia
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Pemafibrate in Hypercholesterolemia report and make more profitable business decisions. This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Pemafibrate in Hypercholesterolemia Drug Details: Pemafibrate (Parmodia) acts as dyslipidemic agent. It...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Pemafibrate in Primary Biliary Cholangitis (Primary Biliary Cirrhosis)
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Pemafibrate in Primary Biliary Cholangitis (Primary Biliary Cirrhosis) report and make more profitable business decisions. This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Pemafibrate in Primary Biliary Cholangitis (Primary Biliary...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Pegozafermin in Metabolic Dysfunction-Associated Steatohepatitis (MASH)
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Pegozafermin in Metabolic Dysfunction-Associated Steatohepatitis (MASH) report and make more profitable business decisions. This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Pegozafermin in Metabolic Dysfunction-Associated Steatohepatitis (MASH) Drug Details: pegozafermin...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – YH-25724 in Obesity
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - YH-25724 in Obesity report and make more profitable business decisions. This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. YH-25724 in Obesity Drug Details: YH-25724 is under development for the treatment...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – LY-3885125 in Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD)
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - LY-3885125 in Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD) report and make more profitable business decisions. This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. LY-3885125 in Metabolic Dysfunction-Associated Steatotic Liver Disease...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Pegozafermin in Liver Cirrhosis
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Pegozafermin in Liver Cirrhosis report and make more profitable business decisions. This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Pegozafermin in Liver Cirrhosis Drug Details: pegozafermin (BIO89-100) is under development...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Pegozafermin in Fibrosis
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Pegozafermin in Fibrosis report and make more profitable business decisions. This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Pegozafermin in Fibrosis Drug Details: pegozafermin (BIO89-100) is under development for the...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – IVB-001 in Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD)
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - IVB-001 in Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD) report and make more profitable business decisions. This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. IVB-001 in Metabolic Dysfunction-Associated Steatotic Liver Disease...